Skip to main content

Advertisement

Table 5 Mexican launch dates of drugs used to treat different types of cancer

From: The impact of pharmaceutical innovation on cancer mortality in Mexico, 2003–2013

Cancer site Drug Launch year
C00–C14 head and neck cancer Docetaxel 1995
C00–C14 head and neck cancer Cetuximab 2004
C15 esophageal cancer Docetaxel 1995
C15 esophageal cancer Trastuzumab 2000
C16 stomach (gastric) cancer Docetaxel 1995
C16 stomach (gastric) cancer Trastuzumab 2000
C18, C20 colon and rectal cancer Irinotecan 1998
C18, C20 colon and rectal cancer Capecitabine 2000
C18, C20 colon and rectal cancer Oxaliplatin 2002
C18, C20 colon and rectal cancer Cetuximab 2004
C18, C20 colon and rectal cancer Bevacizumab 2005
C18, C20 colon and rectal cancer Panitumumab 2011
C18, C20 colon and rectal cancer Aflibercept 2014
C25 pancreatic cancer Paclitaxel 1995
C25 pancreatic cancer Gemcitabine 1997
C25 pancreatic cancer Irinotecan 1998
C25 pancreatic cancer Erlotinib 2006
C25 pancreatic cancer Everolimus 2006
C25 pancreatic cancer Sunitinib 2006
C34 lung cancer Carboplatin 1992
C34 lung cancer Docetaxel 1995
C34 lung cancer Paclitaxel 1995
C34 lung cancer Gemcitabine 1997
C34 lung cancer Vinorelbine 1998
C34 lung cancer Gefitinib 2004
C34 lung cancer Bevacizumab 2005
C34 lung cancer Pemetrexed 2005
C34 lung cancer Erlotinib 2006
C34 lung cancer Topotecan 2008
C34 lung cancer Crizotinib 2012
C40–C41 bone cancer Denosumab 2012
C43 melanoma Interferon alfa-2b 1987
C43 melanoma Aldesleukin 1996
C43 melanoma Peginterferon alfa-2b 2001
C43 melanoma Ipilimumab 2012
C43 melanoma Vemurafenib 2012
C44 basal cell carcinoma Imiquimod 1999
C45 malignant mesothelioma Pemetrexed 2005
C46 kaposi sarcoma Interferon alfa-2b 1987
C46 kaposi sarcoma Paclitaxel 1995
C49 soft tissue sarcoma Imatinib 2001
C49 soft tissue sarcoma Trabectedin 2010
C49 soft tissue sarcoma Pazopanib 2012
C50 breast cancer Epirubicin 1987
C50 breast cancer Goserelin 1991
C50 breast cancer Docetaxel 1995
C50 breast cancer Paclitaxel 1995
C50 breast cancer Gemcitabine 1997
C50 breast cancer Anastrozole 1998
C50 breast cancer Raloxifene 1998
C50 breast cancer Toremifene 1999
C50 breast cancer Capecitabine 2000
C50 breast cancer Letrozole 2000
C50 breast cancer Trastuzumab 2000
C50 breast cancer Exemestane 2004
C50 breast cancer Everolimus 2006
C50 breast cancer Fulvestrant 2009
C50 breast cancer Ixabepilone 2009
C50 breast cancer Lapatinib 2009
C50 breast cancer Trastuzumab emtansine 2014
C53 cervical cancer Bevacizumab 2005
C53 cervical cancer Topotecan 2008
C56 ovarian, fallopian tube, or primary peritoneal cancer Carboplatin 1992
C56 ovarian, fallopian tube, or primary peritoneal cancer Paclitaxel 1995
C56 ovarian, fallopian tube, or primary peritoneal cancer Gemcitabine 1997
C56 ovarian, fallopian tube, or primary peritoneal cancer Bevacizumab 2005
C56 ovarian, fallopian tube, or primary peritoneal cancer Topotecan 2008
C61 prostate cancer Flutamide 1987
C61 prostate cancer Mitoxantrone 1987
C61 prostate cancer Leuprorelin 1989
C61 prostate cancer Goserelin 1991
C61 prostate cancer Docetaxel 1995
C61 prostate cancer Bicalutamide 1997
C61 prostate cancer Degarelix 2010
C61 prostate cancer Cabazitaxel 2012
C64–C65 kidney (renal cell) cancer Aldesleukin 1996
C64–C65 kidney (renal cell) cancer Bevacizumab 2005
C64–C65 kidney (renal cell) cancer Everolimus 2006
C64–C65 kidney (renal cell) cancer Sunitinib 2006
C64–C65 kidney (renal cell) cancer Temsirolimus 2011
C64–C65 kidney (renal cell) cancer Pazopanib 2012
C71 brain tumors Temozolomide 1999
C71 brain tumors Bevacizumab 2005
C71 brain tumors Everolimus 2006
C73 thyroid cancer Vandetanib 2014
C81 hodgkin lymphoma Brentuximab vedotin 2014
C82–C85 non-hodgkin lymphoma Interferon alfa-2b 1987
C82–C85 non-hodgkin lymphoma Rituximab 1999
C82–C85 non-hodgkin lymphoma Bortezomib 2006
C82–C85 non-hodgkin lymphoma Lenalidomide 2008
C82–C85 non-hodgkin lymphoma Plerixafor 2009
C82–C85 non-hodgkin lymphoma Brentuximab vedotin 2014
C90 multiple myeloma and other plasma cell neoplasms Zoledronic acid 2001
C90 multiple myeloma and other plasma cell neoplasms Bortezomib 2006
C90 multiple myeloma and other plasma cell neoplasms Lenalidomide 2008
C90 multiple myeloma and other plasma cell neoplasms Plerixafor 2009
C91, C92 leukemia Interferon alfa-2b 1987
C91, C92 leukemia Mitoxantrone 1987
C91, C92 leukemia Idarubicin 1992
C91, C92 leukemia Rituximab 1999
C91, C92 leukemia Imatinib 2001
C91, C92 leukemia Dasatinib 2007
C91, C92 leukemia Nilotinib 2007
C91, C92 leukemia Clofarabine 2009
C91, C92 leukemia Obinutuzumab 2014